Area of research
Hepatology · Epidemiology
Research interest
Research interests include Liver Diseases and Immunity, Liver Disease Diagnosis and Treatment, Gallbladder and Bile Duct Disorders, and Liver Disease and Transplantation.
Optimising Primary thErapy in pRimAry biliary cholangitis (OPERA): protocol for a randomised, double-blind, placebo-controlled trial of enhanced primary therapy with obeticholic acid.
Polyunsaturated fatty acid-induced metabolic exhaustion and ferroptosis impair the anti-tumour function of MAIT cells in MASLD
Safety and efficacy of elafibranor in primary sclerosing cholangitis: The ELMWOOD phase II randomized-controlled trial
Severe Cholestasis Predicts Recurrent Primary Sclerosing Cholangitis Following Liver Transplantation.
Cilofexor in non-cirrhotic primary sclerosing cholangitis (PRIMIS): a randomised, double-blind, multicentre, placebo-controlled, phase 3 trial
FP7 Bexotegrast improves markers and symptoms of cholestasis and stabilizes markers of liver fibrosis in participants with primary sclerosing cholangitis
Nebokitug, an Anti-chemokine (C-C Motif) Ligand 24 Monoclonal Antibody, in Patients With Primary Sclerosing Cholangitis: A Phase 2 Study.
Implementation of a care bundle improves PBC management
A disease-associated gene desert directs macrophage inflammation through ETS2
Dynamics of Liver Stiffness Measurement and Clinical Course of Primary Biliary Cholangitis
Primary biliary cholangitis drug evaluation and regulatory approval: Where do we go from here?
Critical shortfalls in the management of PBC: Results of a UK-wide, population-based evaluation of care delivery
Loss of biochemical response at any time worsens outcomes in UDCA-treated patients with primary biliary cholangitis
The Role of CCL24 in Primary Sclerosing Cholangitis: Bridging Patient Serum Proteomics to Preclinical Data
Loss of biochemical response at any time worsens outcomes in UDCA-treated patients with primary biliary cholangitis
Serologic extracellular matrix remodeling markers are related to fibrosis stage and prognosis in a phase 2b trial of simtuzumab in patients with primary sclerosing cholangitis.
Longer transplant-free and liver-related event-free survival in obeticholic acid-treated patients with primary biliary cholangitis compared to external controls from two large real-world cohorts
Type of calcineurin inhibitor and long-term outcomes following liver transplantation in patients with primary biliary cholangitis – an ELTR study
Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain?
Safety, tolerability, and efficacy of maralixibat in adults with primary sclerosing cholangitis: Open-label pilot study
CCL24 regulates biliary inflammation and fibrosis in primary sclerosing cholangitis
CCL24 regulates biliary inflammation and fibrosis in primary sclerosing cholangitis
Optimizing therapy in primary biliary cholangitis: Alkaline phosphatase at six months identifies one‐year non‐responders and predicts survival
Safety, tolerability, and efficacy of maralixibat in adults with primary sclerosing cholangitis: Open-label pilot study.
Critical shortfalls in the management of PBC: Results of a UK-wide, population-based evaluation of care delivery
Regulation of immune responses in primary biliary cholangitis: a transcriptomic analysis of peripheral immune cells.
Utility of ElastPQ point-shear wave elastography in the work-up of patients with primary sclerosing cholangitis.
Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis
Greater Transplant-Free Survival in Patients Receiving Obeticholic Acid for Primary Biliary Cholangitis in a Clinical Trial Setting Compared to Real-World External Controls
Liver transplant‐free survival according to alkaline phosphatase and <scp>GLOBE</scp> score in patients with primary biliary cholangitis treated with ursodeoxycholic acid